Alx Oncology Holdings (ALXO) Payables (2019 - 2026)
Alx Oncology Holdings recorded quarterly Payables of $3.9 million in Q1 2026, down 21.57% quarter-over-quarter from $4.9 million in Q4 2025, and down 2.11% year-over-year from $3.9 million in Q1 2025.
Alx Oncology Holdings' Payables history runs 8 years deep, the most recent figure standing at $3.9 million for Q1 2026.
- In Q1 2026, Payables fell 2.11% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (down 2.11% YoY), while the FY2025 annual figure was $4.9 million, up 9.27% from the prior year.
- Payables came in at $3.9 million for Q1 2026 at Alx Oncology Holdings, down from $4.9 million in the prior quarter.
- In the past five years, Payables ranged from a high of $13.0 million in Q3 2023 to a low of $3.9 million in Q1 2026.
- A 5-year average of $6.7 million and a median of $6.2 million in 2024 frame the typical range for Payables.
- On a YoY basis, Payables climbed as much as 121.11% in 2023 and fell as far as 52.59% in 2023.
- Alx Oncology Holdings' Payables stood at $8.1 million in 2022, then gained by 6.42% to $8.6 million in 2023, then tumbled by 47.65% to $4.5 million in 2024, then grew by 9.27% to $4.9 million in 2025, then decreased by 21.57% to $3.9 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $3.9 million, $4.9 million, and $6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | 3.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.85 Mn |
| Dec 31, 2025 | 4.91 Mn |
| Sep 30, 2025 | 6.58 Mn |
| Jun 30, 2025 | 4.90 Mn |
| Mar 31, 2025 | 3.94 Mn |
| Dec 31, 2024 | 4.50 Mn |
| Sep 30, 2024 | 7.89 Mn |
| Jun 30, 2024 | 8.15 Mn |
| Mar 31, 2024 | 6.23 Mn |
| Dec 31, 2023 | 8.59 Mn |
| Sep 30, 2023 | 13.00 Mn |
| Jun 30, 2023 | 4.12 Mn |
| Mar 31, 2023 | 9.83 Mn |
| Dec 31, 2022 | 8.07 Mn |
| Sep 30, 2022 | 5.88 Mn |
| Jun 30, 2022 | 8.68 Mn |
| Mar 31, 2022 | 5.13 Mn |
| Dec 31, 2021 | 3.76 Mn |
| Sep 30, 2021 | 3.68 Mn |
| Jun 30, 2021 | 5.81 Mn |
| Mar 31, 2021 | 7.35 Mn |
| Dec 31, 2020 | 4,000.00 |
| Sep 30, 2020 | 1.42 Mn |
| Jun 30, 2020 | 1.87 Mn |
| Dec 31, 2019 | 3.75 Mn |